Kate Bingham

Managing Partner

In her 26 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

She is one of five Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund (with greater than $2 billion in total assets) for life sciences investing in US and Europe. Kate is responsible for biotech investments and activities in the EU and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. These investments include small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas.

Kate played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.

Prior experience
Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.

Academic credentials
First class degree, Biochemistry, Oxford University; MBA, Harvard Business School (Baker Scholar).

Outside of SV
Kate won the Lifetime Achievement Award, presented by BioIndustry Association UK in January 2017. Kate also serves on the Board of the Francis Crick Institute, serves as Deputy Chairman of St Paul’s Girls’ School, London, and sits on the Investment Committee of Oxford University Spin-out Equity Management (OSEM). At weekends Kate spends time in Wales where she rides horses and mountain bikes, grows vegetables and competes in bog snorkelling competitions.

SV Investment Advisors


Terri Spires